Biomarin announced that the Phase 2 study of BMN-111, the first potential pharmacological therapy for achondroplasia, has just started

Biomarin has just announced that the phase 2 study with the first potential pharmacological therapy for achondroplasia has just started today.

Here goes the link for the press release: Biomarin. 

To learn more about CNP and BMN-111, visit the English page of this blog, to find links to all articles about this peptide and its analogue already published here.